As the cancer survivor’s populace continues to grow, it has become critical to understand the nature and impact that prior cancer cases may have on improving the results recorded in trials, patient experience, as well as the observational studies. It is vital to note that despite the increased numbers of cancer survivors, these survivors continue to be excluded from observational research, as well as the clinical studies. The aging population has been termed as being behind the increase in the number of survivors.
Currently, many survivors go-on to live for more than 10 years after their initial cancer diagnosis. An additional two-thirds live for more than 5 years after this diagnosis. There is a need to understand that these survivors have very complex health needs that need to be addressed. Some of their needs include:
• Surveillance to prevent recurrence
• Continued monitoring for toxic effects associated with cancer treatment
• Management of emerging diagnosis, e.g., new primary cancers or chronic diagnoses.
Exclusion of cancer survivors from clinical trials means that close to a quarter of all patients that have recently been diagnosed with lung cancer will be prevented from taking part in the studies. In order to understand the implications of incident cancer in terms of research and treatment, there is a need to understand the prevalence of prior cancer in patients who have dealt with incident cancer in the past.
He is the CEO and Co-founder of Tempus. This is a technology company that is accredited with creating an operating system to be used in the fight against cancer. Mr. Lefkofsky is also one of the founding partners in a venture fund that invests in disruptive technologies called Lightbank.
Eric Lefkofsky together with his wife Liz began the Lefkofsky Family Foundation in 2006. It is a private charitable foundation whose sole purpose was to enhance lives in the communities where it operates. Apart from serving as a trustee for various organizations in his home city of Chicago, he also is also an author and an adjunct professor.
Read More : https://www.tempus.com/about-us/